Allogene Therapeutics Announces Removal of FDA Clinical Hold Across All AlloCAR T™ Clinical TrialsGlobeNewsWire • 01/10/22
Allogene Therapeutics to Present at the Virtual 40th Annual J.P. Morgan Healthcare ConferenceGlobeNewsWire • 01/04/22
Allogene Therapeutics Expands Headquarters to Support Company Growth and Pipeline InnovationGlobeNewsWire • 12/15/21
Allogene Therapeutics Reports Positive Results from Phase 1 UNIVERSAL Study of Single Dose ALLO-715 AlloCAR T™ Cell Therapy in Relapsed/Refractory Multiple Myeloma at the 63rd American Society of Hematology Annual MeetingGlobeNewsWire • 12/13/21
Allogene Therapeutics Reports Positive Phase 1 Data from the ALPHA Trials in Non-Hodgkin's Lymphoma at the 63rd Annual Meeting of the American Society of HematologyGlobeNewsWire • 12/13/21
Allogene Therapeutics Announces Conference Call to Review ALPHA, ALPHA2 and UNIVERSAL Phase 1 Data Presented at the 2021 American Society of Hematology Annual MeetingGlobeNewsWire • 12/01/21
Allogene Therapeutics Announces Participation in Five Upcoming Virtual Investor ConferencesGlobeNewsWire • 11/12/21
Allogene Therapeutics' (ALLO) CEO David Chang on Q3 2021 Results - Earnings Call TranscriptSeeking Alpha • 11/05/21
Allogene Therapeutics Reports Third Quarter 2021 Financial Results and Business UpdateGlobeNewsWire • 11/04/21
Allogene Therapeutics to Showcase Clinical Data from the ALPHA, ALPHA2 and UNIVERSAL AlloCAR T™ Trials at the 63rd Annual Meeting of the American Society of HematologyGlobeNewsWire • 11/04/21
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Allogene Therapeutics, Inc. - ALLOPRNewsWire • 11/04/21
Allogene Therapeutics to Report Third Quarter Financial Results on November 4, 2021GlobeNewsWire • 10/28/21
Why Shares of Allogene Therapeutics, Beam Therapeutics, Intellia Therapeutics, and Schrödinger Are Volatile This WeekThe Motley Fool • 10/15/21
Are Options Traders Betting on a Big Move in Allogene (ALLO) Stock?Zacks Investment Research • 10/11/21
Allogene Craters To 52-Week Low On FDA Clinical Hold Of CAR-T Trials, Drags Peers As WellBenzinga • 10/08/21
Should you buy or sell ALLO stock after shares plunge 37% as FDA halts clinical trial?Invezz • 10/07/21
Allogene Therapeutics Reports FDA Clinical Hold of AlloCAR T Trials Based on a Single Patient Case in ALPHA2 TrialGlobeNewsWire • 10/07/21